BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections.

BioTryp’s technology targets bacteria’s key defense mechanism, offering an alternative to traditional antibiotic treatments. The company’s small molecules are designed to block the communication process that bacteria use to make a biofilm.

The first indication for the company’s innovative approach is Urinary Tract Infections (UTIs), aiming to revolutionize UTI treatment by targeting bacterial biofilms forming on the bladder wall and urinary catheters. UTIs are the most common bacterial infection and the leading cause of bloodstream infections. Affecting 1 in 2 women and 1 in 10 men, UTIs are responsible for 17% of all hospital-acquired bloodstream infections.

Subscribe for alerts on new companies featured on Startups.Bio

View all recently featured startups